

BC Cancer ST Program Updates for May, 2022

AFFECTED APPLICATION(S)	PowerChart: Oncology/Hematology Regimens and PowerPlans
AFFECTED AREA(S)	BC Cancer VC (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- **For PowerPlans that are versioned:** If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop up window will appear to indicate a new version is required.
 - Click **Yes** to accept the new version.
 - **Do not** use the Copy Forward functionality to ensure that the updates apply.



- **IMPORTANT:** Any change from the standard treatment regimen (dose modification, addition of pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being ordered with the new version (see additional documentation regarding versioning).

Please see this month's changes below:

PowerPlan: LYMECHLOR

Cycles/PowerPlans: All associated Regimens and PowerPlans

Changes:

The drug name for mechlorethamine has now changed to chlormethine.

The regimen description and PowerPlan has been updated to reflect this change.

ONC LY LYMECHLOR (PO) (Pending)

▼ Hide additional details

Regimen description: Treatment for Topical chlormethine in Cutaneous T-cell Lymphoma

Versioning: No

Jira: CST-165338

PowerPlan: ULKMDSA

Cycles/PowerPlans: All associated PowerPlans

Changes:

In the chemotherapy phase, the order comment for azacitidine has been updated to remove "round according to protocol".

ONCP LK ULKMDSA (5 Days On, 2 Days Off, 2 Days On) - Cycle 1, Chemotherapy (Day 1 to 5, 8 to 9) (Future Pending) *Est. 23-

Component	Day 1	Day 2	Fu
prochlorperazine 10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to azaCITIDine. Days 1, 2, 3, 4, 5, 8, 9	Future Pending *Est. 23-Apr-2022 08:...	Future Pending *Est. 24-Apr-2022 08:...	Fu
Treatment Regimen	Planned	Planned	
Zero Time	0 hr	0 hr	
azaCITIDine (azaCITIDine - oncology) 75 mg/m2, subcutaneous, once oncology, drug form: ... Doses greater than 4 mL should be divided into two syrin...	Planned	Planned	
Additional Orders Any additional orders will be displayed below. Please review and adjust scheduled administration time as nee...			
Schedulable Orders Infusion Chemotherapy Visit Within 2 Weeks, Cycle 1: Chair time 55 minutes; Nurse time ...			

▼ Details for azaCITIDine (azaCITIDine - oncology)

Order comments
Doses greater than 4 mL should be divided into two syringes and administered at two separate sites. Days 1, 2, 3, 4, 5, 8, 9

Versioning: No

Jira: CST-165366

PowerPlan: LKAMLAS

Cycles/PowerPlans: All associated PowerPlans

Changes:

In the chemotherapy phase, the order comment for azacitidine has been updated to remove “round according to protocol”.

ONCP LK LKAMLAS Pre-BMT Cycle 1 (5 Days On, 2 Days Off, 2 Days On) - Cycle 1, Chemotherapy (Day 1 to 5, 8 to 9)			
		Day 1	Day 2
	Component	Future Pending *Est. 23-Apr-2022 08:...	Future Pending *Est. 24-Apr-2022 08:...
		Actions	Actions
<input checked="" type="checkbox"/>	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to azaCITIDine. Days 1 to 5, 8, 9	-30 min Planned	-30 mi Planned
<input type="checkbox"/>	prochlorperazine 10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to azaCITIDine. Days 1 to 5, 8, 9	-30 min	-30 mi
Treatment Regimen			
<input checked="" type="checkbox"/>	Zero Time	0 hr Planned	0 hr Planned
<input checked="" type="checkbox"/>	azaCITIDine (azaCITIDine - oncology) 75 mg/m2, subcutaneous, once oncology, drug form: ... Doses greater than 4 mL should be divided into two syrin...	Planned	Planned
	See Prescriptions OR Prescriptions (Inpatient Use Only) Phase for SORafenib		
Additional Orders			

Details for azaCITIDine (azaCITIDine - oncology)	
Details	Order Comments
Order comments	Doses greater than 4 mL should be divided into two syringes and administered at two separate sites. Days 1 to 5, 8, 9

Ondansetron order is now mandatory and prochlorperazine order is now optional. The yellow note “if prochlorperazine is ineffective” has been removed.

ONCP LK LKAMLAS Pre-BMT Cycle 1 (5 Days On, 2 Days Off, 2 Days On) - Cycle 1, Ch		
		Day
	Component	Future f *Est. 23-App
Pre-Medications		
	Patient to take own supply of pre-medications. RN/Pharmacist to confirm	
<input checked="" type="checkbox"/>	ondansetron 8 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to azaCITIDine. Days 1 to 5, 8, 9	Plan
<input type="checkbox"/>	prochlorperazine 10 mg, PO, once oncology, drug form: tab, Use Patient Supply 30 minutes prior to azaCITIDine. Days 1 to 5, 8, 9	
Treatment Regimen		

Versioning: Yes

Jira: CST-165367

PowerPlan: GIAJCAPOX, GIAVRALOX, GICAPOX, GICOXB, GIGAJCOX, GIGAVCOX, GIGAVCOXT, GIRAJCOX, UGI0 CAP

Cycles/PowerPlans: All associated PowerPlans

Changes:

For the CAP PowerPlans:

- A yellow note “ Choose if adding oxaliplatin:” was added .
- The dextrose 5% (D5W) continuous infusion order was modified to include two sentences for 250 mL and 500 mL options.
- A yellow note was added above dextrose 5% (D5W) continuous infusion “To reduce incidence of vascular pain:”

ONCP GI UGI0 CAP Day 1 (every 7 Days) - Cycle 1, Chemotherapy (Day 1) (Future Pending) *E...

Component	Day 1
Choose if ordering etoposide:	Future Pending
For previous etoposide drug reaction:	*Est. 23-Apr-2022 08:...
<input type="checkbox"/> diphenhydrAMINE 50 mg, IV, once oncology, drug form: inj For previous etoposide drug reaction	Actions
<input type="checkbox"/> hydrocortisone 100 mg, IV, once oncology, drug form: inj For previous etoposide drug reaction	
Choose if adding Fluorouracil:	
<input type="checkbox"/> Nursing Reminder	
RIN to assess for stomatitis and diarrhea prior to EACH fluorour...	
Choose if adding oxaliplatin:	
To reduce incidence of vascular pain:	
<input type="checkbox"/> dextrose 5% (dextrose 5% (D5W) continuous infusion)	
▼ 250 mL, Maximum rate of 125 mL/hr, IV, drug form: bag	
250 mL, Maximum rate of 125 mL/hr, IV, drug form: bag	
500 mL, Maximum rate of 250 mL/hr, IV, drug form: bag	
CAP Pharmacist: Remember to add Protocol Code and	

For non CAP PowerPlans:

- The dextrose 5% (D5W) continuous infusion order was modified to include two sentences for 250 mL and 500 mL options.
- A yellow note was added above dextrose 5% (D5W) continuous infusion “To reduce incidence of vascular pain:”

ONCP GI GICOXB - Cycle 2, Chemotherapy (Day 1) (Future Pending) *Est. 23-Apr-2022 08:00 PDT -

Component	Day 1
<input checked="" type="checkbox"/> Zero Time	Future Pending
	*Est. 23-Apr-2022 08:...
	Actions
	0 hr
Oxaliplatin line to be primed with dextrose 5%	Planned
<input checked="" type="checkbox"/> oxaliplatin (oxaliplatin - oncology) 130 mg/m2, IV, once oncology, administer over: 2 hour, dru... Flush line with dextrose 5% pre and post oxaliplatin. Day 1	0 min
	Planned
To reduce incidence of vascular pain:	
<input type="checkbox"/> dextrose 5% (dextrose 5% (D5W) continuous infusion)	0 min
▼ 250 mL, Maximum rate of 125 mL/hr, IV, drug form: bag	
250 mL, Maximum rate of 125 mL/hr, IV, drug form: bag	
500 mL, Maximum rate of 250 mL/hr, IV, drug form: bag	
blood pressure measurement pre and post bevacizumab doses for first 3 cycles and prior to bevacizumab for	

Versioning: Yes

Jira: CST-165471

PowerPlan: BRAVRIBAI

Cycles/PowerPlans: All associated Regimens and PowerPlans

Changes:

BRAVRIBAI Ribociclib Cycles 2 to 6 PowerPlan has been renamed to BRAVRIBAI Ribociclib Cycles 3 to 6.

ONC BR BRAVRIBAI Ribociclib (Pending)

▶ Show additional details

+ Add Document Response View Responses

See also BRAVRIBAI Continuous Hormonal

For premenopausal patients ensure ovarian suppression prior to Cycle 1

→ ONC BR BRAVRIBAI (PO) Pretreatment Plan

Start

- ONC BR BRAVRIBAI Ribociclib Cycle 1 - Cycle 1
- ONC BR BRAVRIBAI Ribociclib Cycle 2 - Cycle 2
- ONC BR BRAVRIBAI Ribociclib Cycles 3 to 6 - Cycle 3
- ONC BR BRAVRIBAI Ribociclib Cycles 3 to 6 - Cycle 4
- ONC BR BRAVRIBAI Ribociclib Cycles 3 to 6 - Cycle 5
- ONC BR BRAVRIBAI Ribociclib Cycles 3 to 6 - Cycle 6
- ONC BR BRAVRIBAI Ribociclib Cycles 7+

A new plan ONC BR BRAVRIBAI Ribociclib Cycle 2 has been created with a Day 15 and 29 lab phase.

ONC BR BRAVRIBAI Ribociclib Cycle 2 - Cycle 2, Labs (Day 15, 29) (Future Pending) *Est. 26-May-2022 08:00 PDT - 29 E		
Component	Day 15	Day 29
	Future Pending	Future Pending
	*Est. 26-May-2022 08:00...	*Est. 09-Jun-2022 08:00...
	Actions	Actions
<input checked="" type="checkbox"/> CBC and Differential Blood, once, Order for future visit	Planned	Planned
<input checked="" type="checkbox"/> Alanine Aminotransferase Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/> Alkaline Phosphatase Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/> Creatinine Level Blood, once, Order for future visit		Planned
<input checked="" type="checkbox"/> If clinically indicated:		
<input type="checkbox"/> Albumin Level Blood, once, Order for future visit		
<input type="checkbox"/> Gamma Glutamyl Transferase Blood, once, Order for future visit		
<input type="checkbox"/> Lactate Dehydrogenase Blood, once, Order for future visit		
<input type="checkbox"/> Sodium and Potassium Panel (Electrolytes Panel Outpat... Blood, once, Order for future visit		
<input type="checkbox"/> Calcium Level Blood, once, Order for future visit		
<input type="checkbox"/> Magnesium Level Blood, once, Order for future visit		
<input type="checkbox"/> Phosphate Level (Phosphorus Level) Blood, once, Order for future visit		
<input type="checkbox"/> Cholesterol Level Blood, once, Order for future visit		
<input type="checkbox"/> Triglyceride Blood, once, Order for future visit		
<input type="checkbox"/> Cancer Antigen 15-3 Blood, once, Order for future visit		
<input type="checkbox"/> Cancer Antigen 125 Blood, once, Order for future visit		
<input type="checkbox"/> Carcinoembryonic Antigen Blood, once, Order for future visit		

Versioning: Yes

Jira: CST-166492

Jira Ticket #	CST-166492, CST-165471, CST-165367, CST-165366, CST-165338
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444